Small molecule tyrosine kinase inhibitors in pancreatic cancer

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 707-715

  Gupta, Sachin ^a   El Rayes, Bassel F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Erlotinib; Pancreatic cancer; Tyrosine kinase inhibitors

Indexed keywords

EID: 77955412358     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Arteaga CL. 2001. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol, 19(18 Suppl):32S-40S.
2. Baker CH, Solorzano CC, et al. 2001. Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. Int J Clin Oncol, 6:59-65.
3. Bergers G, Song S, et al. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest, 111:1287-95.
4. Blaszkowsky LS, Earle C, et al. 2007. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. J Clin Oncol, 2007 ASCO Ann Meeting Proc, 25(25 18S):15080.
5. Bramhall SR, Allum WH, et al. 1995. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg, 82:111-5.
6. Brand RE, Tempero MA. 1998. Pancreatic cancer. Curr Opin Oncol, 10:362-6.
7. Bruns CJ, Kohl G. 2003. Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR(KDR)-TKI), ina model od ZD1839 (Iressa) resistance. Proc Am Soc Clin Oncol, 44:4880.
8. Bruns CJ, Shrader M, et al. 2002. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer, 102:101-8.
9. Buchler P, Reber HA, et al. 2002. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg, 236:738-49; discussion 749.
10. Burris HA 3rd, Moore MJ, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol, 15:2403-13.
11. Chen J, Rocken C, et al. 2006. The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett, 233:328-37.
12. Cherrington JM, Strawn LM, et al. 2000. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res, 79:1-38.
13. Ciardiello F, Caputo R, et al. 2003. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res, 9:1546-56.
14. Conrad C, Ischenko I, et al. 2007. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs, 18:569-79.
15. Dong M, Nio Y, et al. 1998. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res, 18:4613-9.
16. Dvorak HF. 2002. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 20:4368-80.
17. Ebert M, Yokoyama M, et al. 1995. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer, 62:529-35.
18. El-Rayes BF, Philip PA. 2003. A review of systemic therapy for advanced pancreatic cancer. Clin Adv Hematol Oncol, 1:430-4.
19. Epelbaum R, Gluzman SJ, et al. 2007. Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. ASCO 2007 Gastrointestinal Cancers Symposium. Abstr 202.
20. Ferrara N. 1999. Molecular and biological properties of vascular endothelial growth factor. J Mol Med, 77:527-43.
21. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med, 285:1182-6.
22. Gharibo MM, Juvidian P, et al. 2005. Phase II trial of Gleevec (Imatinib mesylate) in patients with metastatic unresectable pancreatic cancer. J Clin Oncol, 2005 ASCO Ann Meeting Proc, 23(16S):4183.
23. Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev, 79:1283-316.
24. Hess V, Glimelius B, et al. 2008. CA19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol, 9:132-8.
25. Hicklin DJ, Ellis LM. 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23:1011-27.
26. Hubbard SR. 2006. EGF receptor activation: push comes to shove. Cell, 125:1029-31.
27. Hwang RF, Yokoi K, et al. 2003. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res, 9:6534-44.
28. Iannitti D, Dipetrillo T, et al. 2005. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol, 28:570-5.
29. Ikeda N, Adachi M, et al. 1999. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer, 79:1553-63.
30. Inai T, Mancuso M, et al. 2004. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol, 165:35-52.
31. Itakura J, Ishiwata T, et al. 2000. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer, 85:27-34.
32. Jemal A, Siegel R, et al. 2007. Cancer statistics, 2007. CA Cancer J Clin, 57:43-66.
33. Kleespies A, Jauch KW, et al. 2006. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? Drug Resist Updat, 9:1-18.
34. Kuo T, Kaiser FA, et al. 2006. A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol, 2006 ASCO Ann Meeting Proc, 24(18S):4122.
35. Lemoine NR, Hughes CM, et al. 1992. The epidermal growth factor receptor in human pancreatic cancer. J Pathol, 166:7-12.
36. Levitzki A. 1999. Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther, 82:231-9.
37. Levitzki A, Gazit A. 1995. Tyrosine kinase inhibition: an approach to drug development. Science, 267:1782-8.
38. Li J, Kleeff J, et al. 2004. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol, 25:203-10.
39. Louvet C, Labianca R, et al. 2005. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol, 23:3509-16.
40. Luo J, Guo P, et al. 2001. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer, 92:361-9.
41. McGartland LP, Rademaker A, et al. 2006. Phase I/II study of imatinib mesylate and gemcitabine for advanced pancreas cancer. ASCO 2006 Gastrointentinal Cancers Symposium, Abstr 132.
42. Mendelsohn J, Baselga J. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21:2787-99.
43. Mendelsohn J, Baselga J. 2006. Epidermal growth factor receptor targeting in cancer. Semin Oncol, 33:369-85.
44. Moore MJ, Goldstein D, et al. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960-6.
45. Niedergethmann M, Hildenbrand R, et al. 2002. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas, 25:122-9.
46. Oettle H, Post S, et al. 2007. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA, 297:267-77.
47. Olayioye MA, Neve RM, et al. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J, 19:3159-67.
48. Ostman A. 2004. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev, 15:275-86.
49. Papageorgio C, Perry MC. 2007. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Cancer Invest, 25:647-57.
50. Philip P, Benedetti J, et al. 2007. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients woth locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol, 25:965s.
51. Pietras K, Rubin K, et al. 2002. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res, 62:5476-84.
52. Regine WF, Abrams RA. 2006. Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol, 33(Suppl 11):S10-3.
53. Ritter CA, Arteaga CL. 2003. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol, 30(Suppl 1):3-11.
54. Rocha Lima CM, Green MR, et al. 2004. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol, 22:3776-83.
55. Rugo HS, Herbst RS, et al. 2005. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol, 23:5474-83.
56. Safran H, Miner K et al. 2006. GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. J Clin Oncol, 2006 ASCO Ann Meeting Proc, 24(18S):4002.
57. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell, 103:211-25.
58. Siu LL, Awada A, et al. 2006. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res, 12:144-51.
59. Spano JP, Kim S, et al. 2006. A phase I study of Axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer. J Clin Oncol, 2006 ASCO Ann Meeting Proc, 24(18S):13092.
60. Spano JP, Chodkiewicz C, et al. 2008. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. XXXX.
61. Summy JM, Gallick GE. 2003. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev, 22:337-58.
62. Thomas SM, Brugge JS. 1997. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol, 13:513-609.
63. Vervenne W, Humblet Y, et al. 2008. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol, 2008 ASCO Annual Meeting, 26(Suppl):abstr 4507).
64. Wallace JA, Nattam S, et al. 2007. Sorafenib plus gemcitabine for advanced pancreatic cancer: A phase II trial of the University of Chicago Phase II Consortium. Journal of Clinical Oncol, 2007 ASCO Ann Meeting Proc, 25(18S) 4608.
65. Wilhelm SM, Carter C, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64:7099-109.
66. Wood JM, Bold G, et al. 2000. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res, 60:2178-89.
67. Yamanaka Y, Friess H, et al. 1993. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res, 13:565-9.
68. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2:127-37.
69. Yokoi K, Sasaki T, et al. 2005. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res, 65:10371-80.